BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3081282)

  • 1. Determination of tissue plasminogen activator and its "fast" inhibitor in plasma.
    Chmielewska J; Wiman B
    Clin Chem; 1986 Mar; 32(3):482-5. PubMed ID: 3081282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of plasminogen activator inhibitor in plasma using t-PA and a chromogenic single-point poly-D-lysine stimulated assay.
    Eriksson E; Rånby M; Gyzander E; Risberg B
    Thromb Res; 1988 Apr; 50(1):91-101. PubMed ID: 3135638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Quantification of a specific inhibitor (PAI-1) of tissue-type plasminogen activator (t-PA) in the plasma].
    Masson C; Angles-Cano E
    Ann Biol Clin (Paris); 1989; 47(5):269-74. PubMed ID: 2500878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased concentration of the fast-acting plasminogen activator inhibitor in plasma associated with familial venous thrombosis.
    Jørgensen M; Bonnevie-Nielsen V
    Br J Haematol; 1987 Feb; 65(2):175-80. PubMed ID: 3103670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurements of the concentration of free plasminogen activator inhibitor (PAI-1) and its complex with tissue plasminogen activator in human plasma.
    Takada Y; Takada A
    Thromb Res Suppl; 1988; 8():15-22. PubMed ID: 3144765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standardization of methods for measuring plasminogen activator inhibitor activity in human plasma.
    Chandler WL; Loo SC; Nguyen SV; Schmer G; Stratton JR
    Clin Chem; 1989 May; 35(5):787-93. PubMed ID: 2498016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Release pattern of the vascular plasminogen activator and its inhibitor in human postvenous occlusion plasma as assessed by a spectrophotometric solid-phase fibrin-tPA activity assay.
    Anglés-Cano E; Boutière B; Arnoux D; Masson C; Contant G; Benchimol P; Sampol J
    Thromb Haemost; 1987 Oct; 58(3):843-9. PubMed ID: 3124285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase.
    Kruithof EK; Tran-Thang C; Bachmann F
    Thromb Haemost; 1986 Feb; 55(1):65-9. PubMed ID: 3085266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
    Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR
    J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic analysis of the interaction between plasminogen activator inhibitor-1 and tissue-type plasminogen activator.
    Masson C; Angles-Cano E
    Biochem J; 1988 Nov; 256(1):237-44. PubMed ID: 3146972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasminogen activator inhibitor-1 is the primary inhibitor of tissue-type plasminogen activator in pregnancy plasma.
    Jørgensen M; Philips M; Thorsen S; Selmer J; Zeuthen J
    Thromb Haemost; 1987 Oct; 58(3):872-8. PubMed ID: 3124286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma.
    Chmielewska J; Rånby M; Wiman B
    Thromb Res; 1983 Aug; 31(3):427-36. PubMed ID: 20217999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a reversible inhibitor of plasminogen activators in blood plasma.
    Kluft C; Jie AF; Sprengers ED; Verheijen JH
    FEBS Lett; 1985 Oct; 190(2):315-8. PubMed ID: 3930295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1).
    Kluft C; Jie AF; Rijken DC; Verheijen JH
    Thromb Haemost; 1988 Apr; 59(2):329-32. PubMed ID: 3133814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A sensitive assay, specific for endothelial cell type plasminogen activator inhibitor in blood plasma.
    Sprengers ED
    Thromb Haemost; 1986 Feb; 55(1):74-7. PubMed ID: 3085268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.
    Thorsen S; Philips M; Selmer J; Lecander I; Astedt B
    Eur J Biochem; 1988 Jul; 175(1):33-9. PubMed ID: 3136015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between age and plasma t-PA, PA-inhibitor, and PA activity.
    Hashimoto Y; Kobayashi A; Yamazaki N; Sugawara Y; Takada Y; Takada A
    Thromb Res; 1987 Jun; 46(5):625-33. PubMed ID: 3114907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration.
    Lucore CL; Fujii S; Sobel BE
    Circulation; 1989 Jun; 79(6):1204-13. PubMed ID: 2498004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.
    Hamsten A; Wiman B; de Faire U; Blombäck M
    N Engl J Med; 1985 Dec; 313(25):1557-63. PubMed ID: 3934538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioimmunoassay (BIA) of tissue plasminogen activator (t-PA) and its specific inhibitor (t-PA/INH).
    Mahmoud M; Gaffney PJ
    Thromb Haemost; 1985 Jun; 53(3):356-9. PubMed ID: 3931284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.